Why We Are Raising UnitedHealth's Fair Value Estimate
The firm's near-term outlook looks slightly higher than our expectations.
Narrow-moat UnitedHealth Group (UNH) gave its final outlook for 2020 and its initial outlook for 2021 at its annual investor day. The firm's near-term outlook looks slightly higher than our expectations. Considering that and cash flows generated since our last valuation update, we are raising our fair value estimate 8% to $329 per share from $304 previously.
For 2020 and 2021, the company released guidance that is slightly higher than our expectations, which contributes to our higher fair value estimate roughly equally to recently generated cash flows. Specifically on the final 2020 outlook, management now expects revenue around $257 billion and adjusted earnings per share nearing the higher end of its recently raised guidance range of $16.50-$16.75, up from 16.25-$16.55. These expectations are slightly higher than than our previous estimates ($16.56), and we've raised our 2020 expectation to $16.75, which was not material to our fair value estimate.
For 2021, the company gave an outlook that was roughly in line with our adjusted EPS outlook but higher on the revenue and cash flow lines. This higher cash flow outlook was the main operational driver of our fair value estimate. Of note, the outlook for 2021 is slightly lower than the firm's longer-term outlook (13% to 16% EPS growth) because of ongoing headwinds related to the pandemic and economic downturn ($1.80 of constraints). Our estimate for adjusted EPS remains within the company's target range for 2021 ($17.75-$18.25), which is only 6% to 9% expected growth relative to the high end of 2020's target range. However, we were impressed with the firm's operating cash flow expectation of $20 billion-$21 billion for 2021, which was higher than our previous estimate of $19 billion. We have raised our estimate for next year's cash flow in line with management's outlook, contributing to the increase in our fair value estimate. Most of our other intermediate- and long-term expectations have not changed materially.
|Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.|
Julie Utterback does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.